Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 10, 2010 - Issue 9
Submit an article Journal homepage
623
Views
13
CrossRef citations to date
0
Altmetric
Meeting Report

American Society of Clinical Oncology 2010 colorectal update

Janet E Murphy Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA; Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
&
David P Ryan Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA;[email protected]
Pages 1371-1373 | Published online: 10 Jan 2014

References

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
  • Alberts SR, Sargent DJ, Smyrk TC et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. J. Clin. Oncol.28(18 Suppl.) (2010) (Abstract CRA3507).
  • Goldberg RM, Sargent DJ, Thibodeau SN et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3508).
  • Maughan TS, Adams R, Smith CG et al.; MRC COIN Trial Investigators. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin–fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3502).
  • Tabernero J, Aranda E, Gomez A et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3501).
  • McCahill LE, Yothers GA, Sharif S et al. A Phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (Bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: results of NSABP C-10. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3527).
  • Ngan S, Fisher R, Goldstein D et al. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3509).
  • Schrag D, Weiser MR, Goodman KA et al. Neoadjuvant FOLFOX–Bev, without radiation, for locally advanced rectal cancer. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3511).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.